Clinical Trials Logo

Clinical Trial Summary

The study evaluates the efficacy of 1 week of tDCS (5 sessions) placebo in reducing alcohol consumption within the 24 weeks following the treatment in non-abstinent patients with alcohol use disorders versus placebo.


Clinical Trial Description

340 patients are expected and randomized in two groups: 170 patients with active tDCS and 170 patients with placebo tDCS Visit 1 : Patients will received one daily session (13:20:13) during 5 consecutive days: current flows continuously twice for 13min with a rest interval (no stimulation) of 20 min. Visit 1 to 7 : Change from baseline to week 24 in Total Alcohol Consumption (TAC) and Number of Heavy Drinking Days (HDD) will be evaluated in each group. Evaluation on alcohol consumption (daily drinking diary, alcohol craving and severity) and other assessments like mood, quality of life, safety. The co-primary outcome of change from baseline in total alcohol consumption AND reduction in number of heavy drinking days at 6 months after treatment and its association with tDCS will be analyzed under the intention-to-treat principle using a mixed model repeated measures (8 times). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02505126
Study type Interventional
Source Centre Hospitalier Universitaire Dijon
Contact
Status Completed
Phase N/A
Start date November 23, 2015
Completion date December 23, 2021

See also
  Status Clinical Trial Phase
Completed NCT00372749 - Does the Threat of an Aversive Reaction Affect Craving of Alcohol During Cue Exposure in Alcohol Dependent Patients? N/A
Completed NCT01323738 - Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics N/A